1 Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis Comprehensive Cancer Center
2 Disclosures Research grants AstraZeneca/Medimmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Eli Lilly, Merck, Novartis Consultant Ariad Pharmaceuticals, AstraZeneca, Bayer, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Eli Lilly, Liquid Genomics, Merck, Mirati, Novartis, Peregrine, Pfizer, Response Genetics, Synta Pharmaceuticals
3 Disclaimer Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF and in the US under the brand name GILOTRIF for use in patients with distinct types of EGFR mutation positive NSCLC. In Switzerland, GIOTRIF is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with common activating EGFR mutation(s) (exon 19 deletions or exon 21 L858R substitution). The recommended dose is 40 mg once daily with no possibility for dose escalation. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in uncommon mutations and SqCC of the Lung and other indications in Switzerland.
4 Evolution in Therapeutic Landscape: A Compartmental Algorithm (2014) Patients with advanced stage NSCLC (PS 0 1) Oncogene-driven Non-squamous Non-oncogenedriven Squamous All First-line TKI (targeted therapy) therapy doublet +/ bev therapy doublet First-line maintenance EGFR mutation ALK translocation Pem or bev Or erlotinib therapy Or erlotinib Second-line therapy +/ TKI 2 nd -gen TKI therapy Or erlotinib therapy Or erlotinib Third-line therapy therapy therapy Or erlotinib Or erlotinib ALK, anaplastic lymphoma kinase; Bev, bevacizumab; EGFR, epidermal growth factor receptor; Gen, generation; NSCLC, non-small cell lung cancer; Pem, pemetrexed; PS, performance status; TKI, tyrosine kinase inhibitor. Adapted from Gandara DR, et al. Clin Lung Cancer. 2017;18:1 4.
5 Compartmental Treatment Algorithm: October st line Oncogene- Driven TKI (targeted therapy) EGFR, ALK, ROS1 Patients with Advanced NSCLC (PS 0-1) Non-squamous Squamous PD-L1+ PD-L1 PD-L1+ PD-L1 PD-1 doublet PD-1 doublet (± Neci ) 1 st line Maintenance TKIs PD-1 Pem/Bev PD-1 2 nd line 3 rd -gen TKIs EGFR/ALK Other TKIs PD-1/PD-L1 ( ± Ramu) PD-1/PD-L1 (± Ramu) PD-1/PD-L1 (+/- Ramu) PD-1/PD-L1 (+/- Ramu) 3 rd line doublet ALK, anaplastic lymphoma kinase; Bev, bevacizumab; EGFR, epidermal growth factor receptor; Gen, generation; NSCLC, non-small cell lung cancer; Pem, pemetrexed; PS, performance status; TKI, tyrosine kinase inhibitor. Adapted from Gandara DR, et al. Clin Lung Cancer. 2017;18:1 4. Or Afatinib Or Afatinib
6 Compartmental Treatment Algorithm: Squamous Lung Cancer Patients with Advanced NSCLC (PS 0 1) Squamous PD-L1+ PD-L1 First-line PD-1 doublet (+/- Neci ) First-line maintenance PD-1 PD-1/PD-L1 PD-1/PD-L1 Second-line (+/ ramu) (+/ ramu) Or afatinib (not suitable for immunotherapy) Third-line Or afatinib Or afatinib, chemotherapy; IOs, immuno-oncology therapies; Neci, necitumumab; NSCLC, non-small cell lung cancer; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; PS, performance status; Ramu, ramucirumab;, negative; +, positive. Adapted from Gandara DR, et al. Clin Lung Cancer. 2017;18:1 4.
7 Patient Case: Advanced Recurrent SqCLC Presentation: 66-year-old woman with 50 pack per year smoking history presents with cough and fatigue (PS=1) At presentation Diagnosis: Stage IIIA NSCLC of squamous histology RUL peri-hilar mass with mediastinal LNs Mediastinoscopy positive for right levels R4 and 7 LNs MRI of brain negative LN, lymph nodes; MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer; PS, performance status; RUL, right upper lobe; RT, radiotherapy
8 Patient Case Continued Advanced, Recurrent SqCLC First-line treatment: Cisplatin-etoposide plus concurrent radiotherapy Relapse 18 months later in lung primary and bones (T2 shown) and adrenal glands; PS=1 At recurrence PS, performance status; SqCLC, squamous cell lung cancer.
9 Patient Case Continued Advanced, Recurrent SqCLC Question 1: In this patient with newly found SqCLC (Stage IV), would you test for PD-L1 in anticipation of possible PD-1/PD-L1-directed therapy? 1. Yes 2. No PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; SqCLC, squamous cell lung cancer.
10 Patient Case Continued Advanced, Recurrent SqCLC You decide to test for PD-L1 status by IHC assay Question 2: You have a variety of tests available to you through an outside CLIA-certified lab; which one of the following would you order? IHC assay (Dako) 2. 22C3 IHC assay (Dako) 3. SP263 IHC assay (Ventana) 4. SP142 (Ventana) CLIA, clinical laboratory improvement amendments; IHC, immunohistochemistry; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; SqCLC, squamous cell lung cancer.
11 Patient Case Continued Advanced, Recurrent SqCLC PD-L1 testing by the Dako 22C3 IHC assay reveals a PD-L1 level of 55% Question 3: What treatment would you recommend for this patient who has a Zubrod performance score of 1? 1. You do not recommend immunotherapy at this particular time 2. Pembrolizumab based on PD-L1 >50% 3. Nivolumab regardless of PD-L1 level 4. Nivolumab based on PD-L1 >50% 5. Atezolizumab regardless of PD-L1 level IHC, immunohistochemistry; PD-L1, programmed death ligand 1; SqCLC, squamous cell lung cancer.
12 Patient Case Continued Advanced, Recurrent SqCLC The patient receives nivolumab and has a partial response that is maintained for 6 months (see scan) At that time, she develops progressive disease in multiple sites, including chest wall mass and worsening bone metastases (PS=1) In this patient who initially received platinum-based chemotherapy and then secondline immunotherapy, you decide to initiate third-line therapy IV, intravenous; SqCLC, squamous cell lung cancer.
13 Patient Case Continued Advanced, Recurrent SqCLC Question 4: Which of the available therapeutic options for advanced SqCLC would you employ? 1. Afatinib 2. Docetaxel + ramucirumab 3. Docetaxel alone PD-1, programmed cell death 1; PS, performance status; SqCLC, squamous cell lung cancer.
14 Patient Case Continued Advanced, Recurrent SqCLC You decide to treat with afatinib Question 5: Which of the following tests have proven useful in predicting the benefit of afatinib in patients with SqCLC? 1. EGFR protein expression by IHC 2. EGFR gene copy number by FISH 3. EGFR viii mutation 4. No predictive biomarker is necessary prior to employing afatinib in advanced SqCLC EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; SqCLC, squamous cell lung cancer.
15 The Patient is Treated with Afatinib 40 mg/day After recurrent mild diarrhea the dose is reduced to 30 mg/day with good tolerability afterwards Bone pain is reduced and PS remains 1 Repeat PET/CT scan at 3 months is consistent with stable disease CT, computerized tomography; PET, positron emission tomography; PS, performance status.
16 Emerging Treatment Algorithm for First-line Therapy of Advanced SqCLC: 2017 PD-L1 50% PD-L1 <50% Pembrolizumab Gemcitabine/platinum or Paclitaxel/carboplatin or Nab-pac/carboplatin or Gemcitabine/platinum Necitumumab Nab-pac, nab-paclitaxel; PD-L1, programmed death ligand 1; SqCLC, squamous cell lung carcinoma. Adapted from Gandara DR, et al. Clin Lung Cancer. 2017;18:1 4.
17 Turning Advanced Squamous Cell Lung Cancer into a Chronic Disease Requisites to turn squamous cell lung cancer into a chronic disease: Multiple therapeutic options Based on individual patient characteristics: age, PS, co-morbidities Based on biomarker status (PD-L1) for immunotherapy in first-line treatment Multiple lines of therapy 1 st -line 2 nd -line 3 rd -line 4 th -line Which therapy to employ and when to do so is now individualized on a patient-by-patient basis (Precision Medicine) PD-L1, programmed death ligand 1; PS, performance status. Gandara DR, et al. Clin Cancer Res. 2015;21:
18 KEYNOTE-024: Pembrolizumab Versus Platinum-Doublet therapy in First-line Treatment of Advanced NSCLC 1 2 Key eligibility criteria Untreated Stage IV NSCLC PD-L1 TPS 50% ECOG PS 0 1 No activating EGFR mutation or ALK translocation No untreated brain metastases No active autoimmune disease requiring systemic therapy R (1:1) N=305 Pembrolizumab 200 mg IV Q3W (2 years) Platinum-doublet chemotherapy (4 6 cycles) PD * Crossover to Pembrolizumab 200 mg Q3W for 2 years Key endpoints Primary: PFS (RECIST v1.1 per blinded, independent central review) Secondary: OS, ORR and safety Exploratory: DOR *To be eligible for crossover, PD had to be confirmed by blinded, independent central radiology review and all safety criteria had to be met. ALK, anaplastic lymphoma kinase; DOR, duration of response; ECOG PS, Eastern Cooperative Group performance status; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD, disease progression; ORR, objective response rate; OS, overall survival; PFS, progression free survival; R, randomization; PD-L1, programmed death ligand 1; Q3W, every three weeks; TPS, tumor proportion score. 1. Reck M, et al. Ann Oncol 2016;27(suppl 6):abstract LBA08; 2. Reck M, et al. N Engl J Med. 2016;375:
19 KEYNOTE-024: Pembrolizumab Versus Platinum-doublet therapy 1 2 PFS (primary endpoint) OS (secondary endpoint), chemotherapy; CI, confidence interval; HR, hazard ratio; mo, months; OS, overall survival; PFS, progression free survival; Pembo, pembrolizumab. 1. Reck M, et al. N Engl J Med. 2016;375: ; 2. NICE Single Technology Appraisal committee papers [ID990].
20 Emerging Treatment Algorithm for Advanced SqCLC in 2017: Second-line and Beyond If 1 st -line immunotherapy given If 1 st -line chemotherapy given 2 nd -line options Gemcitabine/platinum or Gemcitabine/platinum + necitumumab or Paclitaxel/carboplatin or Nab-pac/carboplatin 3 rd -line options Afatinib or Docetaxel ± ramucirumab 2 nd -line options Nivolumab or pembrolizumab (PD-L1 1%) or atezolizumab Nab-pac, nab-paclitaxel; PD-L1, programmed death ligand 1; SqCLC, squamous cell lung cancer.
21 Phase III Trials of PD-1/PD-L1 therapy compared to Docetaxel in 2nd/3rd-Line Advanced/Metastatic NSCLC Nivolumab All comers Strategy: (PD-L1+ & PD-L1-) Pembrolizumab Marker positive Strategy: PD-L1+ Atezolizumab Marker positive Strategy: PD-L1+ (TC+ ITL) POSITIVE POSITIVE POSITIVE IV, intravenous; NSCLC, non-small cell lung cancer; OS, overall survival; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; Pembro, pembrolizumab; Q2W, every 2 weeks; Q3W, every 3 weeks. 1. Brahmer J, et al N Engl J Med; 373:123 35; 2. Borghaei H, et al. N Engl J Med. 2015;373: ; 3. Herbst RS, et al. Lancet. 2016;387: ; 4. Rittmeyer A, Gandara DR, et al. Lancet. 2017;389:
22 PFS (%) OS (%) LUX-Lung 8: Afatinib Versus Erlotinib in Lung SqCLC Primary endpoint: PFS Secondary endpoint: OS Median PFS, months (95% CI) Afatinib (n=398) 2.6 ( ) Erlotinib (n=397) 1.9 ( ) HR (95% CI) 0.81 ( ) P value P= Afatinib Erlotinib % Median OS, months (95% CI) 36.4% 22.0% Afatinib (n=398) 7.9 ( ) Erlotinib (n=397) 6.8 ( ) HR (95% CI) 0.81 ( ) P value P= Afatinib Erlotinib Months % Objective response rate: 6% vs 3% (P=0.055) Disease control rate: 51% vs 40% (P=0.002) Soria JC, et al. Lancet Oncol. 2015;16: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; QD, daily; SqCLC, squamous cell lung cancer.
23 LUX-Lung 8: Overall Survival Subgroup Analysis Factors No. of Patients HR (95% CI) Overall ( ) Age <65 years ( ) 65 years ( ) Gender Male ( ) Female ( ) Race Non-East Asian ( ) East Asian ( ) ECOG at baseline ( ) ( ) Smoking history Never smoker ( ) Light ex-smoker ( ) Current and other ex-smoker ( ) Histology Squamous ( ) Mixed ( ) Best response to first-line chemotherapy CR/PR ( ) SD ( ) Unknown ( ) 1/16 1/ Favors Afatinib Favors Erlotinib Soria JC, et al. Lancet Oncol. 2015;16: CI, confidence interval; CR, complete response; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; PR, partial response; SD, stable disease.
24 LUX-Lung 8: Patient-reported Outcomes Symptom improvement Time to deterioration Afatinib Erlotinib Number of patients HR (95% Cl) Coughing (Q1 from QLQ-LC13) p=0.03 Coughing (Q1 from QLQ-LC13) ( ) Dyspnea (Q3 Q5 from QLQ-LC13) p=0.06 Dyspnea (Q3 Q5 from QLQ-LC13) ( ) Pain (Q9, Q19 from QLQ-C p=0.78 Pain (Q9, Q19 from QLQ-C30) ( ) GHS/QoL (Q29 Q30 from QLQ-C30) p=0.04 GHS/QoL (Q29 Q30 from QLQ-C30) ( ) /4 1/ Patients with improvement in symptoms (%) Favors afatinib Favors erlotinib GHS, global health status; QoL, quality of life. PRO analysis from LUX-Lung 8 reported in Gadgeel SM, et al; abstract 8100 (poster board 425) presented at ASCO 2015.
26 Faculty Discussion Chair Rolf Stahel University Hospital of Zürich, Switzerland David R. Gandara University of California Davis Cancer Center, USA Noemí Reguart Hospital Clínic de Barcelona, Spain Maximilian Hochmair Otto Wagner Spital, Vienna, Austria 26
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello email@example.com UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
Rebecca (Becky) Fahrenbruch, PharmD, BCOP Oncology Pharmacy Manager U of MN Health Maple Grove Oct 28 th, 2016 Many of these slides were created and presented previously by Erin Kelley, PharmD. She has
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
Squamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression David R. Spigel, M.D. Program Director, Lung Cancer Research Sarah Cannon Research Institute Nashville, TN Case of NR: Initial
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
ESMO IMMUNO-ONCOLOGY CONGRESS 2017 Primary PFS and safety analyses of a randomised Phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
Recent developments and novel strategies to improve current immunotherapeutic approaches in non-small cell lung cancer Jan.firstname.lastname@example.org Antalya, 29 September 2017 Disclosures https://www.betransparent.be/en/search
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
Immunotherapy in Non-Small Cell Lung Cancer Renato G. Martins Stephen H. Petersdorf Endowed Chair in Cancer Care Associate Medical Director, Solid Tumor Adult Oncology, Seattle Cancer Care Alliance Professor,
CONSENSUS OR CONTROVERSY: Clinical Investigators Provide Perspectives on the Treatment of Metastatic Non-Small Cell Lung Cancer in Patients without Targetable Tumor Mutations CME Information TARGET AUDIENCE
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
I CONVEGNO REGIONALE SIFO MEETING DI PRIMAVERA IL FARMACISTA CLINICO E I NUOVI MODELLI DI CURA Taormina, 11/12/13 maggio 217 Stato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer Tu Nguyen-Ngoc, 1 Martin Reck, 2 Daniel SW Tan 3 and Solange Peters 1 1. Department of Medical Oncology, Centre Hospitalier
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
Best of ASCO 214 Lung Heather Wakelee, MD Associate Professor of Medicine, Oncology Stanford Cancer Institute Stanford, California USA Outline ALK: 82: 1st line crizotinib Profile 114 83: ASCEND ceritinib
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
Bristol-Myers Squibb s Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival to More Patients Opdivo is the only
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
DOI 10.1007/s10147-016-1039-0 ORIGINAL ARTICLE Final overall survival in JO22903, a phase II, open label study of first line erlotinib for Japanese patients with EGFR mutation positive non small cell lung
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
Biomarkers for Cancer Immunotherapy Debate Moderator: Maria Karasarides, PhD AstraZeneca Pro: Daniel S. Chen, MD, PhD Genentech Con: Steve Averbuch, MD Bristol-Myers Squibb Biomarkers to Select Patients
For journalists outside the US/UK/Canada only GIOTRIF (AFATINIB*) 1. What is GIOTRIF (afatinib*)? 2. How does GIOTRIF (afatinib*) work? 3. Data overview 4. Clinical potential 5. GIOTRIF (afatinib*) approval
EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA Sze Wai Chan A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial
Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value- Based Price Benchmarks Final Evidence Report and Meeting Summary November 1, 2016 Institute for Clinical and Economic
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
Leading experts discuss treatment strategies for advanced NSCLC. Tulip. X-Ray image courtesy of Bryan Whitney. www.x-rayphotography.com. Best Practices in Treatment Selection for Patients With Advanced
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: email@example.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
Investor Update Basel, 20 November 2017 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening
Last Review Status/Date: December 2015 Page: 1 of 21 Small-Cell Lung Cancer Summary Proteomic testing has been proposed as a way to predict outcomes and response to and selection of targeted therapy for
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
Case Report Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Yu-Ting Wang, Wei-Wei Ning, Jing Li, Jian-n Huang Department of Respiratory Medicine, the First ffiliated
Savolitinib clinical trials June 2016 update List of abbreviations BID Twice Daily MET Aberation of c-met/hgf CRC Colorectal Cancer MTD Maximum Tolerated Dose DoR Duration of Response NSCLC Non-Small Cell